INTRODUCTION
Monoclonal antibodies (mAbs) are among the fastest growing class of therapeutics being developed for a broad range of indications including cancer, inflammatory disorders, and infectious diseases. 1 Many mAb therapeutics like trastuzumab (Herceptin) cost as much as $100,000 annually per patient, 2 resulting in reduced access in many global markets. Due to the inherent high costs associated with antibody manufacturing facilities and processes, biosimilars will only marginally decrease the cost of mAb therapeutics. In addition, the mAb storage conditions and repeated administrations are impractical for many developing countries. A major technological breakthrough is therefore required to make mAb therapeutics available and affordable globally.
One potentially transformative approach to antibody therapy is to manufacture the mAb in the patient. Genes encoding the mAb could be introduced into certain host cells (e.g., muscle), which then serve as the "factory" for in vivo antibody production. Conceptually, such a gene transfer strategy has been demonstrated in animal models using viral vectors such as adeno-associated virus (AAV) providing antibody protection against respiratory syncytial virus (RSV), 3 simian immunodeficiency virus (SIV), 4 HIV type 1 (HIV-1), 5 and influenza viruses. [6] [7] [8] The near permanence of in vivo antibody production elicited by systemic AAV vector delivery renders this approach more similar to vaccination. Although intranasal delivery of AAV offers the potential to decrease the duration of expression, 6 the prolonged persistence of high-level mAb production with systemic AAV delivery raises concerns of adverse consequences that might manifest only months or years later, and this remains a major regulatory hurdle for systemic AAV-mediated antibody gene transfer.
Another approach to antibody gene transfer is to utilize plasmid DNA (pDNA). A vast number of vaccine candidates use pDNA to express antigens in vivo. pDNA has been tested for mAb production because pDNA is easy to manufacture, lacks cold-chain storage requirements, and has a favorable clinical safety profile to date. 9 The transgene transduction and expression are typically low after intramuscular (i.m.) injection, unless in vivo electroporation (EP) is applied concurrently. EP functions through the application of electric pulses resulting in cell membrane destabilization and DNA electrophoresis facilitating DNA delivery into cells. 10 Presumably, mAbs are expressed endogenously by transduced muscle cells and released into the circulation. Previous studies on pDNA/EP for antibody gene transfer have shown that mAbs produced in vivo are functionally intact and can protect mice from influenza, 11, 12 Dengue, 13 or Chikungunya virus challenge. 14 Although some of these studies demonstrated persistence of appreciable in vivo antibody productions for weeks to months, [11] [12] [13] [14] others did not. [15] [16] [17] Importantly, prior pDNA/EP efforts typically yielded low serum/plasma antibody concentrations (<1 mg/mL) [13] [14] [15] [16] while using doses of pDNA (25-300 mg) for a single antibody [11] [12] [13] [14] [15] [16] [17] that are too high to scale up for human use.
Here, we describe a systematic evaluation of pDNA/EP in order to place this platform technology for producing mAbs in vivo on the path for clinical development. Using clinically applicable experimental parameters, including EP conditions that are acceptable in humans and clinically feasible DNA doses, we can now achieve mAb concentrations in mice that are in the therapeutic range for a duration of several months. Moreover, we use this technology to express multiple mAbs in vivo simultaneously and demonstrate their protective efficacy against influenza and Ebola viruses, two of the greatest biothreats today.
RESULTS

Gene Cassette, Regimen, and Vector Optimizations Enhance mAb Expression
EP was previously shown to improve transgene expression of i.m. delivered pDNA. 15, 16 We optimized gene transfer cassettes to minimize the amount of injected pDNA needed to obtain high mAb expression. Here, five gene cassette configurations utilizing the pVAX1 vector (Invitrogen Thermo Fisher Scientific, Grand Island, NY) were evaluated with 5A8, the mouse precursor mAb of an HIV-1 entry inhibitor ibalizumab (iMab) 18, 19 as a model antibody ( Figure S1A ). Co-injection of separate plasmids carrying the heavy-(H) and light (L)-chain genes (H/L) under control of cytomegalovirus (CMV) promoter was compared with a single injection of dual-promoter plasmids containing H-and L-chain genes, as well as singlepromoter plasmid constructs with the H-and L-chain genes separated by a furin cleavage site coupled with a P2A self-processing peptide (2A) 13, 20 or the single-chain variable fragment (scFv) fused to the Fc region known as an immunoadhesin (IA) ( Figure S1A ). 4, 6 All gene expression cassettes produced mAb or mAb-like molecules in vitro ( Figure S1B ) with binding and functional activities comparable with the clinical supply of iMab as assessed by ELISA and HIV-1 neutralization, respectively ( Figure S1C ). When compared following i.m. injection with EP in mice, co-injection of two plasmid gene cassettes (H/L) at a 1:1 ratio resulted in the highest serum mAb concentrations ( Figure 1A) when normalized by the amount of pDNA injected. The serum 5A8 mAb produced by in vivo gene transfer with H/L plasmid gene cassettes was functional as demonstrated by ex vivo neutralization of HIV-1 pseudotyped virus ( Figure S2A ), and dose-dependent mAb expression was observed with pDNA administered via EP ( Figure S2B ).
The amount of pDNA used to generate such levels of functional mAb expression may be too high to translate to clinical application. In order to enhance transgene expression, pretreatment with hyaluronidase was added to the regimen. Hyaluronidase breaks down hyaluronan, a component of the skeletal muscle extracellular matrix, to facilitate DNA diffusion. 11, 21, 22 Consistent with previous reports, 11,12,21,23 2.7-to 2.9-fold higher mAb expression was observed following hyaluronidase pretreatment ( Figure S3 ). Next, we compared mAb expression with two commercially available DNA vaccine vectors, pVAX1 and gWiz (Aldevron, Fargo, ND, USA). Whereas pVAX1 (3.0 kb) is a small basic vector, gWiz (5.1 kb) is larger with the addition of an intron upstream to the transgene and extensive bacterial element orientation/composition optimization. 24 The H-and L-chain genes from two anti-influenza mAbs, C179 25 and S139/1, 26 were cloned into pVAX1 and gWiz. Mice were administered 10 mg H/L pDNA of an individual mAb followed by EP. At day 21, S139/1 and C179 concentrations were 2.6-and 3.0-fold higher, respectively, when the gWiz vector was used compared with the pVAX1 vector ( Figure 1B ). Therefore, gWiz was used as the expression vector for all subsequent studies.
Oligoclonal mAb Responses Induced by pDNA/EP Protect Mice from Influenza Infection
We ultimately aimed to test the prophylactic efficacy of the pDNA/EP mAb gene transfer approach in vivo using an influenza challenge model. To understand the impact of individual versus combination antibodies for influenza prevention, we first evaluated two H3reactive mAbs, S139/1 and 9H10, for protection against influenza A/Aichi/2/68 (H3N2) challenge. Mouse anti-influenza mAbs were used to permit long-term studies in mice without the complication of cross-species anti-mAb responses. All mAbs were constructed utilizing immunoglobulin G2a (IgG2a), which preferentially interacts with Fc receptors for IgG (FcgRs), 27 mAbs. 27, 28 Mice passively infused with 100 mg (5 mg/kg) of either individual mAb 1 day prior to challenge were completely protected from influenza-related mortalities. Although 10 mg of individual mAb (0.5 mg/kg) resulted in significant influenza-related morbidity and mortality, co-administering S139/1 and 9H10 at 10 mg/mAb enhanced the protective capacity of the mAbs resulting in complete protection from influenza-related mortalities, supporting the evaluation of an oligoclonal mAb response as influenza immunoprophylaxis ( Figure S4 ).
To determine whether our gene transfer technology could express numerous mAbs simultaneously, we administered 10 mg of H/L pDNA in the gWiz backbone encoding for each of three anti-influenza mAbs-C179, a group 1 hemagglutinin-stalk-binding mAb, 25 S139/1, a broadly reactive group 1 and 2 head-binding mAb, 26 and 9H10, a group 2 hemagglutinin-stalk-binding mAb 29 -to mice at distinct sites followed by EP. The mAbs were selected such that two mAbs are reactive to both H1 viruses (C179 and S139/1) and H3 viruses (S139/1 and 9H10), the influenza subtypes primarily responsible for seasonal influenza infections, while targeting two different vulnerable sites on each virus. All three mAbs were durably expressed with peak serum mAb concentrations (3.5-4.9 mg/mL) achieved between weeks 4 and 8 with concentrations gradually decreasing to 0.5-0.7 mg/mL by week 43 (Figure 2 ).
Next, we evaluated the protective efficacy of an oligoclonal anti-influenza mAb response generated by pDNA/EP gene transfer against group 1 and 2 influenza challenges. BALB/c mice were injected i.m. in separate limbs with 10 mg of H/L pDNA in the gWiz backbone encoding each C179, S139/1, and 9H10 followed by EP. As controls, BALB/c mice were injected with 10 mg of H/L pDNA encoding each of three anti-Ebola murine mAbs (2G4, 4G7, and 13C6) followed by EP. Expression of individual anti-influenza mAbs was confirmed on days Weight loss in control animals was substantial beginning on day 2, whereas weight loss in mice expressing anti-influenza mAbs was less prominent ( Figure 3A ). Importantly, 9 of the 10 mice expressing anti-influenza mAbs survived the challenge compared with 0 of 8 mice expressing anti-Ebola mAbs (p < 0.0001, log rank test; Figure 3A) . To examine the breadth of this gene transfer strategy, another set of mice treated with pDNA/EP was challenged as described above with 21 MLD 50 of A/Aichi/2/68 (H3N2). Seven of 10 mice survived challenge, although mice expressing anti-influenza mAbs initially became sick as indicated by weight loss ( Figure 3B ). In comparison, the Ebola mAb-expressing mice became ill with greater rapidity and marked weight loss, resulting in protocol mandated humane sacrifice 4-6 days after challenge (p < 0.0001, log rank test; Figure 3B ). These results demonstrate that an oligoclonal anti-influenza mAb response generated in vivo by gene transfer can protect from both group 1 (H1N1) and 2 (H3N2) influenza A strains.
To investigate whether the animals developed heterosubtypic immunity, we challenged the surviving mice from Figure 3 with the heterosubtypic virus 27.5 weeks after gene transfer of the anti-influenza mAb cocktail. Based on pharmacokinetic data from a similar study (Figure 2 ), the expressed serum mAb concentrations by pDNA/EP were expected to be low (0.7-1.5 mg/mL) but significant at the time of the heterosubtypic challenge. The seven mice protected from A/Aichi/2/68 (H3N2) were subsequently challenged with A/WSN/ 33 (H1N1; Figure 4A ), whereas the nine mice protected from A/WSN/33 (H1N1) were subsequently challenged with A/Aichi/ 2/68 (H3N2) ( Figure 4B ). In both cases, 100% of previously challenged mice were protected from heterosubtypic challenge, with minimal weight loss and no mortality observed compared with control mice, all of which succumbed to infection ( Figure 4 ). In fact, protection against mortality was more complete in the second challenge. These results suggest that oligoclonal immunoprophylaxis provided by pDNA/EP not only protects mice from viral challenge ( Figure 3 ), but also most likely permits the generation of a host immune response to a heterologous influenza strain ( Figure 4 ).
Oligoclonal mAb Responses Protect Mice from Ebola Virus Infection
To investigate the robustness of this gene delivery platform, we next applied pDNA/EP to the prevention of a different infectious disease where successful protection has been afforded by oligoclonal mAb responses. The 2014 Ebola virus epidemic in West Africa and the likelihood of future outbreaks highlight the critical need for rapid and effective prophylaxis and treatment options. ZMapp, an mAb cocktail consisting of 13C6, 2G4, and 4G7, is currently the only anti-Ebola mAb cocktail used in humans, 30 and it afforded complete protection in macaques when administered as post-exposure prophylaxis within 5 days of challenge. 31 ZMapp components have been tested individually or in other combinations as prophylaxis in mice by passive transfer, 32, 33 whereas the ZMapp combination conferred protection when delivered as prophylaxis by AAV. 34 Here, we evaluated the prophylactic efficacy of ZMapp when delivered by pDNA/EP.
To avoid cross-species immunogenicity, we constructed the ZMapp antibodies with murine IgG2a Fc (mZMapp). Passively administered mZMapp at low (10 mg/mAb; 30 mg total) or high (40 mg/mAb; 120 mg total) doses resulted in mean serum mZMapp concentrations 1 day after injection of 21.2 and 66.4 mg/mL, respectively, and a normal half-life of 6.2-7.2 days ( Figure S6A ). In a follow-up experiment, mice were passively infused with the same mZMapp doses and challenged with 100 plaque-forming units (PFUs) of mouse-adapted Ebola virus (1976 strain, Mayinga 35 ) 1 day after mAb administration. High protective efficacy (17/20 mice; 85%) was observed in mice administered 120 mg of mZMapp (6 mg/kg total mAb; Figure S6B ). However, no significant difference was observed between mice receiving 30 mg of mZMapp (1.5 mg/kg total mAb) and control mice administered 30 mg of S139/1, an anti-influenza mAb serving as control ( Figure S6B ).
We then evaluated a range of pDNA doses (5-50 mg) encoding H/L of each of the three mZMapp mAbs in the gWiz vector in the gene transfer experiments. Serum mZMapp levels were generally pDNA dose dependent, with the highest or lowest levels observed in the group injected with 50 or 5 mg pDNA/mZMapp mAb, respectively. Minimal differences were observed between the groups of mice injected with 10 or 25 mg pDNA/mZMapp mAb ( Figure 5A ). Similar trends were observed 14 days after pDNA/EP administration ( Figure 5B ). Mice (n = 20 per group) were administered 5, 10, 25, or 50 mg of pDNA for each of the three mZMapp mAbs to evaluate the protective efficacy of this pDNA/EP regimen. As controls, mice (n = 30) were administered 150 mg of pDNA encoding H/L of the anti-influenza mAb, S139/1. Blood was collected 14 days after pDNA/EP administration, and the mean total serum mZMapp concentrations were 8.2, 10.7, 13.6, and 35.6 mg/mL, respectively ( Figure 5B ). The mice were subsequently challenged 28 or 31 days after pDNA/EP administration with 100 PFUs of a mouse-adapted Ebola virus (1976 strain, Mayinga 35 ). Complete protection from death was observed in the mice administered 10 or 50 mg of pDNA/mZMapp mAb ( Figure 5C ). One mouse administered 25 mg of pDNA/mZMapp mAb succumbed to disease on day 7 after challenge, resulting in 95% (19/20 mice) protection. At a dose of 5 mg of pDNA/mZMapp mAb, 70% (14/20 mice) protection was noted. In contrast, all 30 control mice succumbed to infection 3-8 days after challenge ( Figure 5C ). Interestingly, all mice in the 5 mg pDNA group displayed signs of infection 4 days after challenge ( Figure 5D ). In comparison, 7 of 20 mice in the 10 mg pDNA group exhibited signs of illness on days 7-8, whereas only 3 of 20 mice in the 25 mg pDNA group exhibited disease signs ( Figure 5D ). Based on previous pharmacokinetic data ( Figure 5A ), the mean total serum mZMapp concentrations at week 5, near the time of challenge, were expected to be 8.8, 11.5, 13.4, and 29.4 mg/mL for the 5, 10, 25, and 50 mg pDNA groups, respectively, indicating a correlation between the total serum mZMapp concentration and protective efficacy. Sustained antibody expression for at least 15 weeks with a half-life of 9.5-12.2 weeks (66-85 days) was observed in mice administered 10 or 50 mg of pDNA/mZMapp mAb prior to a slow decrease in expression ( Figure S7) ; therefore, it is expected that the protective duration provided by pDNA/EP administration might be at least 2-3 months.
DISCUSSION
The current costs associated with mAb therapies, the practicality of passive infusion administration, and the necessity of repeated dosing prohibit global availability. We have aimed to pursue the production of mAb in vivo via gene transfer technologies that could be substantially cheaper and easier, thereby expanding access to antibody medicines in areas beyond the wealthier nations. Here, we report the results of our gene transfer experiments using pDNA delivered by EP to produce multiple functional mAbs in mice. We believe our indepth studies have moved pDNA/EP beyond preliminary reports, placing this platform technology on a solid foundation for clinical development. For our efficacy experiments in mice, we used doses of pDNA (5-10 mg) that are scalable for humans, in contrast to previous studies (25-300 mg). [11] [12] [13] [14] [15] [16] [17] Despite lower inoculum of pDNA, we observed higher mAb expression with mean peak serum concentrations (3-5 mg/mL) ( Figure 2 ) that are 3-to 10-fold higher than previous findings. [13] [14] [15] [16] [17] Furthermore, mAb concentrations remained 1 mg/mL for up to 32 weeks (Figure 2 ), which is more persistent that previously described, 14, 16, 17 therefore potentially extending the therapeutic window for treatment and prevention. The observed serum antibody concentrations fall well within the therapeutic range for many mAbs in clinical use today, 1, 36 and the duration of antibody expression bodes well for infrequent administration of pDNA/EP. It is worth noting that in our studies, animals were challenged 3-4 weeks after DNA/EP administration, implying the durability of protection and potentially impacting disease prevention in developing regions.
We demonstrate that our pDNA/EP gene transfer platform can produce functional mAbs in vivo against viral pathogens that are among the greatest biothreats to humanity today. Specifically, the expressed mAbs conferred solid protection against parenteral challenges with A B influenza viruses (groups 1 and 2) or a strain of Ebola virus. We note that we achieved protection using weakly neutralizing first generation mAbs. Much more potent mAbs directed against influenza and Ebola viruses have been developed, [37] [38] [39] [40] [41] [42] [43] [44] and their protective efficacies are expected to be even more superior when delivered by pDNA/EP. We also note that our current study demonstrates simultaneous expression of multiple mAbs in vivo, which may be crucial in affording protection because it has the potential of providing greater activity and/or breadth.
Multiple gene transfer approaches are being pursued to express therapeutic mAbs in vivo. AAV delivery of mAb genes into muscle can yield high levels of antibody expression that continues for years. 4, 45 However, the near permanence of antibody expression poses significant regulatory concerns that must be overcome, unless an effective "off switch" could be engineered. Delivery of gene-encoding RNA could also result in the production of a protein or mAb in vivo. 46 Therapeutic serum concentrations could be attained acutely, but the translational half-life is typically in the order of hours to a day, 47 yielding a pharmacokinetic profile similar to the passive infusion of the therapeutic protein or mAb at best. 46 Comparing and contrasting these gene transfer approaches with our findings using pDNA/EP, the current "sweet spot" of potential clinical use appears to be years for AAV, months for DNA, and days for RNA delivery strategies. Antibody expression durations of several months can be ideal for situations such as seasonal outbreaks when permanent expression is unnecessary, providing a therapeutic window sufficient to impact when global prevention access is limited. Additionally, the development of heterosubtypic immunity during antibody expression has broad implications for protection against diverse influenza strains.
The EP device we utilized here (Ichor's TriGrid Delivery System 48 ), along with the electric field parameters, not only boosted the immunogenicity of a DNA vaccine, but also demonstrated an acceptable safety, tolerability, and acceptance profile in humans. 49 One challenge we face in moving this pDNA/EP technology into human use involves scaling from mice to humans, which may be addressed in part by engineering mAbs with improved pharmacokinetics and plasmid vectors with enhanced expression. 50 In addition, it is important to note that EP devices and conditions in clinical use today were designed years ago. Recent advances made in the field of EP in vivo will likely improve the expression level. 51 Furthermore, to date, EP has largely been applied to DNA vaccination, where a certain degree of cell death and inflammation is beneficial to the generation of an immune response. On the other hand, persistent and prolonged mAb production in vivo demands EP parameters that minimize cell death and immune recognition. We therefore firmly believe there is a lot of room for EP optimization (electric field settings and electrode arrays) that could overcome the challenges in the mouse-to-human scale-up. If successful, gene transfer via pDNA/EP could become a transformative platform technology that lowers the cost of and expands access to mAb therapy worldwide.
MATERIALS AND METHODS
Plasmid Construction
All 5A8 expression cassettes were separately constructed by PCR amplification and separately cloned into the pVAX1 expression plasmid at the NheI and XhoI restriction sites. IgG2a H-and L-chain DNA encoding C179, 25 S139/1 (GenBank: 4GMT_I and 4GMT_M), 9H10 (kindly provided by Dr. Peter Palese), 2G4 (patent US20120283414), 4G7 (patent US20120283414), and 13C6 (patent US6875433 B2) were optimized and synthesized (GeneArt Gene Synthesis, Thermo Fisher Scientific, Waltham, MA, USA) and cloned separately into the pVAX1 or gWiz expression plasmids. pDNA was isolated using EndoFree Plasmid Maxi kits (QIAGEN, Valencia, CA, USA). DNA yield and quality were confirmed by spectrophotometry and agarose gel electrophoresis.
Influenza Virus Production and Quantification
The mouse-adapted A/WSN/33 strain was obtained by passaging the virus seven times in BALB/c mice as previously described. 52 The MLD 50 was determined in BALB/c mice. Mouse-adapted, BALB/c-titrated A/Aichi/2/68 was prepared as previously described. 53 
Mice, EP, and Virus Challenges Animal Ethics Statement
Animals were maintained at the Comparative Bioscience Center of The Rockefeller University or at the US Army Medical Research Institute of Infectious Diseases (USAMRIID) facility in accordance with the regulations of the Institutional Animal Care and Use Committee (IACUC) of the housing institute. All animal studies were conducted under protocols approved by the IACUC of The Rockefeller University or the USAMRIID in compliance with the Animal Welfare Act and other federal statutes and regulations relating to animals and experiments involving animals.
pDNA/EP Administration
Six-to ten-week-old female BALB/c mice (Charles Rivers Laboratories) were administered pDNA by i.m. injection with EP using the TriGrid Delivery System (Ichor Medical Systems, San Diego, CA, USA) using conditions previously described. 48 Briefly, the electrode array consisted of an array of four penetrating needle-type electrodes 4 mm in length arranged in two interlocking equilateral triangles to form a diamond shape with an intraelectrode spacing of 2.5 mm. The electrode array included a central injection port designed to interface with a 0.3 cc insulin syringe and 30G injection needle (Becton Dickinson, Franklin Lakes, NY, USA). During administration, the electrode array and injection needle were inserted into the target administration site with the major axis of the array aligned with the orientation of the muscle fibers at the injection site. Following i.m. injection of the DNA, electrical stimulation was applied via the surrounding array of electrodes at an amplitude of 62.5 V (250 V/cm of electrode spacing) for a duration of 40 ms applied over a period of 400 ms (a 10% duty cycle). For hyaluronidase pretreatment, mice were injected i.m. with bovine hyaluronidase (Sigma, St. Louis, MO, USA) or PBS 2 hr prior to i.m. injection of pDNA with EP. For oligoclonal experiments, pDNA encoding H-and L-chains of one antibody were mixed, and pDNA encoding each antibody was injected in muscles in separate limbs to yield authentic antibodies. Mice were bled retroorbitally, and serum was isolated and frozen until analysis.
Influenza Prophylaxis in Mice
Influenza virus was thawed and diluted in PBS to deliver the indicated dose in 30 mL. Mice were anesthetized by isoflurane inhalation, and 15 mL of diluted virus was instilled into each nostril. Mice were weighed daily for 10 days after challenge and sacrificed when weight loss was >20% of starting weight as per IACUC regulations. Animal numbers per group were calculated to obtain statistical difference between no survival in the control group and at least 70% effectiveness in the treated groups with >90% power using a two-sided alpha level of 0.05.
Ebola Virus Prophylaxis in Mice
Mice were housed at the Comparative Bioscience Center of The Rockefeller University and administered pDNA/EP as described. Treated mice were then transported to the Biosafety Level 4 containment animal facility at USAMRIID, where the thoroughly validated lethal mouse-adapted Ebola virus mouse model was developed. 54 The mice were challenged intraperitoneally with 100 PFU of mouse-adapted Ebola virus (1976 strain, Mayinga 35 ) and monitored daily for 21 days postinfection. Animal numbers per group (n = 20) were calculated to obtain statistical difference between 10% survival in the control group and at least 50% effectiveness in the treated groups with >90% power using a two-sided alpha level of 0.05.
ELISAs
Detection of 5A8 by sCD4 Binding
Plates coated with human soluble CD4 were blocked and incubated with mouse sera for 1 hr. Binding was detected using horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG1 H&L (Bethyl Laboratories, Montgomery, TX, USA) or alkaline phosphatase (AP)-conjugated anti-mouse antibodies, and developed by 3,3 0 ,5,5 0tetramethylbenzidine (TMB) or AMPAK kit (DAKO; Carpinteria, CA, USA). mAb concentration was determined by comparing absorbance values with the CD4 binding curve of purified 5A8 protein.
Detection of Mouse Anti-Influenza mAbs C179, S139/1, and 9H10
For co-expression studies, to discriminate the expression of S139/1 and 9H10, both recognizing H3 epitopes, S139/1 was detected using the HA1 subunit and 9H10 was detected with H10N8. ELISA plates were coated with 100 ng of Zaire GPDTM in 0.1 M NaHCO 3 (pH 9.6) per well overnight at 4 C. Plates were washed and blocked with 5% milk and 0.5% BSA in PBS containing 0.05% Tween 20. Mouse sera were serially diluted in blocking buffer and incubated on the ELISA plate for 1 hr at 37 C. After washing, goat anti-mouse IgG HRP (Enzo Life Sciences, Plymouth Meeting, PA, USA) was added for 1 hr at 37 C. Bound mAb was detected using TMB Liquid Substrate (Sigma) and stopped with 1N H 2 SO 4 . Spectrophotometric readings were performed at 450 nm with a 570 nm reference subtraction. Purified proteins were used for the standard curve.
Statistical Methods
All statistical comparisons were performed using GraphPad Prism Software, version 6 (La Jolla, CA, USA). An unpaired two-tailed t test was used to assess weight loss differences in surviving mice. Survival differences were analyzed using the Mantel-Cox log rank test with the Bonferroni correction performed for multiple comparisons. 
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